Trial · NCT01511107
Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
NCT01511107, Phase 2, Terminated, Alejandro Hoberman; results first posted 2017-02-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance. Trials, record NCT01511107. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01511107
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance
- NCT number
- NCT01511107
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 520 participants, actual
- Lead sponsor
- Alejandro Hoberman
- Conditions
- Acute Otitis Media
- Interventions
- Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days
- First posted
- 2012-01-18
- Last updated
- 2017-10-06
- Results first posted
- 2017-02-10
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM | From 72 hours after randomization until day 21 of the index episode. The mean day for this visit was 13.2. | Proportion of children initially diagnosed with AOM who experience treatment failure at or before the day 12-14 visit. TF is defined as substantial persistence or worsening of symptoms specifically attributable to AOM, or of otoscopic signs of AOM, after 72 hours from the time of randomization, such that additional antimicrobial therapy is deemed advisable. If a parent/legal guardian is unwilling to continue the assigned study product regimen, the participant will be categorized as TF. Should a participant be administered another systemic antibiotic while taking study medication or prior to Day 16, the participant will be considered a TF. Clinical success is defined as complete or substantial resolution of symptoms specifically attributable to AOM for 48 hours and of otoscopic signs of acute inflammation (bulging of the tympanic membrane (TM) or intense erythema), with or without persistence of middle-ear effusion, such that no additional antibiotic therapy is deemed advisable. |
| Secondary | The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit | From 72 hours after the AOM recurrence was diagnosed until day 21 of the recurrence. The mean day for this visit was 13.3. | Proportion of AOM recurrences resulting in treatment failure at or before the day 12-14 visit. TF is defined as substantial persistence or worsening of symptoms specifically attributable to AOM, or of otoscopic signs of AOM, after 72 hours from the time of the recurrence, such that additional antimicrobial therapy is deemed advisable. If a parent/legal guardian is unwilling to continue the assigned study product regimen, the participant will be categorized as TF. Should a participant be administered another systemic antibiotic while taking study medication or prior to Day 16, the participant will be considered a TF. Clinical success is defined as complete or substantial resolution of symptoms specifically attributable to AOM for 48 hours and of otoscopic signs of acute inflammation (bulging of the TM or intense erythema), with or without persistence of middle-ear effusion, such that no additional antibiotic therapy is deemed advisable. |
| Secondary | The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.3. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.4. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Positive Only for One or More Susceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.2. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Positive Only for One or More Susceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.9. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Positive for One or More Nonsusceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The end-of-treatment visit. The mean day for this visit was 13.6. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Positive for One or More Nonsusceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The end-of-treatment visit. The mean day for this visit was 13.4. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of Children Whose Nasopharyngeal (NP) Isolates at Enrollment Are Pathogen Negative or Positive Only for at Least One Susceptible Pathogen Who Become Colonized With Nonsusceptible Pathogens at Any Time Over the Course of Follow-up | Day 1 of study entry until day 365 | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
| Secondary | The Distribution of 6 Week Follow-up, Non-Illness Visits During the Respiratory Season at Which a Nonsusceptible Pathogen is Recovered | Day 1 of study entry until day 244. The respiratory season is October 1 - May 31, inclusive. | AOM pathogens are defined as Streptococcus pneumoniae (S pn) or Haemophilus Influenzae (H flu). In the case of S pn, susceptibility to penicillin was determined as follows: When minimum inhibitory concentration (MIC) was available, susceptible was defined as MIC \<0.1 µg/mL, intermediate as MIC 0.1 to 1 µg/mL, and resistant as MIC \>1 µg/mL. When MIC was not available, susceptible was defined as showing oxacillin disk zone size \>20 mm, intermediate as zone size 9 to 20 mm, and resistant as zone size ≤8 mm. In the case of H flu, susceptible was defined as beta-lactamase-negative and ampicillin E test MIC ≤1 µg/mL; nonsusceptible was defined as either beta-lactamase-positive or beta-lactamase-negative and ampicillin E test MIC \>1 µg/mL. |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM | From 72 hours after randomization until day 21 of the index episode. The mean day for this visit was 13.2. | The analysis was intent to treat (ITT). The number of participants is equal to the number of children randomized \& eligible who had a clinical assessment at or before the day 12-14 visit. | participants | NUMBER |
| SECONDARY | The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit | From 72 hours after the AOM recurrence was diagnosed until day 21 of the recurrence. The mean day for this visit was 13.3. | The analysis was ITT. The number of participants is equal to the number of children randomized \& eligible who had a clinical assessment at or before the day 12-14 visit following an AOM recurrence. | recurrence | NUMBER |
| SECONDARY | The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.3. | The analysis was ITT. The participants are randomized \& eligible children having a NP culture at enrollment that is negative for both S pn and H flu and a NP culture at the day 12-14 visit which is either positive (+) for \>=1 penicillin nonsusceptible pathogen OR pathogen negative (-) or + only for \>=1 penicillin susceptible pathogen. | participants | NUMBER |
| SECONDARY | The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.4. | The analysis was ITT. The participants are randomized \& eligible children having a NP culture at onset that is negative for both S pn and H flu and a NP culture at the day 12-14 visit which is either positive (+) for \>=1 penicillin nonsusceptible pathogen OR pathogen negative (-) or + only for \>=1 penicillin susceptible pathogen. | recurrence | NUMBER |
| SECONDARY | The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Positive Only for One or More Susceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.2. | The analysis was ITT. The participants are randomized \& eligible children having a NP culture at enrollment that is positive only for \>=1 susceptible pathogen \& a NP culture at the day 12-14 visit which is either positive (+) for \>=1 penicillin nonsusceptible pathogen OR pathogen negative (-) or + only for \>=1 penicillin susceptible pathogen. | participants | NUMBER |
| SECONDARY | The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Positive Only for One or More Susceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The day 12-14 visit. The mean day for this visit was 13.9. | The analysis was ITT. The participants are randomized \& eligible children having a NP culture at onset that is positive (+) only for one or more susceptible pathogens \& a NP culture at the day 12-14 visit which is either + for \>=1 penicillin nonsusceptible pathogen OR pathogen negative (-) or + only for \>=1 penicillin susceptible pathogen. | recurrence | NUMBER |
| SECONDARY | The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Positive for One or More Nonsusceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The end-of-treatment visit. The mean day for this visit was 13.6. | The analysis was ITT. The participants are randomized \& eligible children having both a NP culture at enrollment that is positive (+) for one or more nonsusceptible pathogens \& a NP culture at the day 12-14 visit which is either + for \>=1 penicillin nonsusceptible pathogen OR pathogen negative (-) or + only for \>=1 penicillin susceptible pathogen. | participants | NUMBER |
| SECONDARY | The Distribution of AOM Recurrences With a Nasopharyngeal (NP) Culture at Onset That is Positive for One or More Nonsusceptible Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | The end-of-treatment visit. The mean day for this visit was 13.4. | The analysis was ITT. The participants are randomized \& eligible children having a NP culture at onset that is positive (+) for \>=1 nonsusceptible pathogen \& a NP culture at the day 12-14 visit which is either + for \>=1 penicillin nonsusceptible pathogen OR pathogen negative (-) or + only for \>=1 penicillin susceptible pathogen. | recurrence | NUMBER |
| SECONDARY | The Distribution of Children Whose Nasopharyngeal (NP) Isolates at Enrollment Are Pathogen Negative or Positive Only for at Least One Susceptible Pathogen Who Become Colonized With Nonsusceptible Pathogens at Any Time Over the Course of Follow-up | Day 1 of study entry until day 365 | The analysis was ITT. The participants are randomized \& eligible children having both a NP culture at enrollment that is either pathogen negative or positive only for \>=1 susceptible pathogen and a NP culture at some time over the course of followup. | participants | NUMBER |
| SECONDARY | The Distribution of 6 Week Follow-up, Non-Illness Visits During the Respiratory Season at Which a Nonsusceptible Pathogen is Recovered | Day 1 of study entry until day 244. The respiratory season is October 1 - May 31, inclusive. | The analysis was ITT. The participants are randomized \& eligible children with at least one follow-up, nonillness visit, with a nasopharyngeal (NP) culture which is either positive (+) for \>=1 penicillin nonsusceptible pathogens or positive (+) only for \>=1 penicillin susceptible pathogens or pathogen negative (-). | Visit | NUMBER |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 outcomesResults by group116
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM | Amoxicillin-Clavulanate, 10 Days | Treatment failure | 39 | participants | |
| The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM | Amoxicillin-Clavulanate, 5 Days | Treatment failure | 77 | participants | |
| The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM | Amoxicillin-Clavulanate, 10 Days | Treatment success | 199 | participants | |
| The Distribution of Children Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit Specific to the Index Episode of AOM | Amoxicillin-Clavulanate, 5 Days | Treatment success | 152 | participants | |
| The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit | Amoxicillin-Clavulanate, 10 Days | Treatment failure | 25 | recurrence | |
| The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit | Amoxicillin-Clavulanate, 5 Days | Treatment failure | 29 | recurrence | |
| The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit | Amoxicillin-Clavulanate, 10 Days | Treatment success | 108 | recurrence | |
| The Distribution of AOM Recurrences Categorized as Treatment Failure (TF) at or Before the Day 12-14 End-of-Treatment Visit | Amoxicillin-Clavulanate, 5 Days | Treatment success | 73 | recurrence | |
| The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | Amoxicillin-Clavulanate, 10 Days | + for nonsusceptible pathogen(s) day 12-14 | 15 | participants | |
| The Distribution of Children With a Nasopharyngeal (NP) Culture at Enrollment That is Negative for AOM Pathogens in Which the Follow-up NP Culture at Day 12-14 Yields a Nonsusceptible Pathogen | Amoxicillin-Clavulanate, 5 Days | + for nonsusceptible pathogen(s) day 12-14 | 11 | participants |
1 to 10 of 116Source ClinicalTrials.gov
See all 116 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Amoxicillin-Clavulanate, 10 Days | 260 | |
| Overall Study | STARTED | Amoxicillin-Clavulanate, 5 Days | 260 | |
| Overall Study | COMPLETED | Amoxicillin-Clavulanate, 10 Days | 238 | |
| Overall Study | COMPLETED | Amoxicillin-Clavulanate, 5 Days | 219 | |
| Overall Study | NOT COMPLETED | Amoxicillin-Clavulanate, 10 Days | 22 | |
| Overall Study | NOT COMPLETED | Amoxicillin-Clavulanate, 5 Days | 41 |
Source ClinicalTrials.gov
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Non-protocol acute otitis media (AOM) | Ear and labyrinth disorders | Amoxicillin-Clavulanate, 10 Days | 44 | 257 | 48 |
| other | Non-protocol acute otitis media (AOM) | Ear and labyrinth disorders | Amoxicillin-Clavulanate, 5 Days | 48 | 258 | 60 |
| other | Gastroenteritis | Gastrointestinal disorders | Amoxicillin-Clavulanate, 10 Days | 29 | 257 | 31 |
| other | Gastroenteritis | Gastrointestinal disorders | Amoxicillin-Clavulanate, 5 Days | 27 | 258 | 28 |
| other | Protocol defined diarrhea | Gastrointestinal disorders | Amoxicillin-Clavulanate, 10 Days | 84 | 257 | 112 |
| other | Protocol defined diarrhea | Gastrointestinal disorders | Amoxicillin-Clavulanate, 5 Days | 91 | 258 | 105 |
| other | Vomiting | Gastrointestinal disorders | Amoxicillin-Clavulanate, 10 Days | 54 | 257 | 62 |
| other | Vomiting | Gastrointestinal disorders | Amoxicillin-Clavulanate, 5 Days | 51 | 258 | 61 |
| other | Fever | General disorders | Amoxicillin-Clavulanate, 10 Days | 44 | 257 | 58 |
| other | Fever | General disorders | Amoxicillin-Clavulanate, 5 Days | 42 | 258 | 45 |
1 to 10 of 44Source ClinicalTrials.gov
See all 44 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Amoxicillin-Clavulanate, 10 Days | ||
| Total, all-cause mortality | Amoxicillin-Clavulanate, 5 Days | ||
| Total, other adverse events | Amoxicillin-Clavulanate, 10 Days | 240 | 257 |
| Total, other adverse events | Amoxicillin-Clavulanate, 5 Days | 242 | 258 |
| Total, serious adverse events | Amoxicillin-Clavulanate, 10 Days | 3 | 257 |
| Total, serious adverse events | Amoxicillin-Clavulanate, 5 Days | 5 | 258 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Amoxicillin-Clavulanate, 10 Days vs Amoxicillin-Clavulanate, 5 Days: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01511107
GET https://conductscience.org/api/trials/v1/NCT01511107/registered?page=2